Innovative dual-functional hybrid cationic PEGylated proniosomes as a smart nano-platform for Boosted vaginal delivery: multi-level in-vitro, ex-vivo, microbiological, and in-vivo studies

<b>Introduction:</b> Vaginal candidiasis remains a recurrent fungal infection affecting millions of women worldwide, necessitating innovative local delivery systems to overcome poor drug solubility and mucosal barriers. This study introduces Dual-Functional Hybrid Cationic PEGylated Proniosomes (DHCPP) as a smart nano-platform designed to boost the vaginal delivery of Fenticonazole Nitrate (FTN). <b>Methods:</b> DHCPP systems were fabricated via the coacervation phase separation method and optimized using a full 2<sup>3</sup> factorial design, achieving a high desirability value of 0.931. The optimized DHCPP exhibited an encapsulation efficiency of 91.61%, particle size of 238.85 nm, and zeta potential of +58.85 mV, ensuring colloidal stability and efficient mucosal interaction. <b>Results:</b> <i>In-vitro</i> characterization using TEM and FTIR verified the formation of uniform spherical vesicles and successful FTN encapsulation without chemical incompatibility. Mucoadhesion testing revealed superior adhesive strength, indicating prolonged vaginal residence, while drug release followed a diffusion-controlled pattern. The optimized DHCPP was incorporated into a carbopol-based gel exhibiting pseudo-plastic rheology and pH compatibility with the vaginal environment. Multi-scale <i>ex vivo</i> and <i>in vivo</i> evaluations revealed a 2.36-fold permeation enhancement compared to FTN gel, consistent with deeper mucosal penetration observed via confocal microscopy. The microbiological assessment indicated a pronounced reduction in MIC and MFC values and a remarkable improvement in biofilm inhibitory effect, highlighting enhanced antifungal efficacy. Histopathological examination verified the mucosal safety of the optimized gel. <b>Conclusion:</b> The developed DHCPP represents an innovative, multifunctional, and biocompatible delivery system offering enhanced vaginal permeation, prolonged retention, and potent antifungal activity for the effective management of vaginal candidiasis.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-01-28
DOI
https://doi.org/10.3389/fphar.2025.1746918
Citations
3
Primary Topic
Advanced Drug Delivery Systems
Type
article
Field-Weighted Citation Impact
83.40
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Innovative dual-functional hybrid cationic PEGylated proniosomes as a smart nano-platform for Boosted vaginal delivery: multi-level in-vitro, ex-vivo, microbiological, and in-vivo studies

Islam M. Adel, Abdurrahman M. Fahmy, Heba Attia, Sadek Ahmed et al.
3 citations
Frontiers in Pharmacology
Advanced Drug Delivery Systems
83.40
article

Innovative dual-functional hybrid cationic PEGylated proniosomes as a smart nano-platform for Boosted vaginal delivery: multi-level in-vitro, ex-vivo, microbiological, and in-vivo studies

Islam M. Adel, Abdurrahman M. Fahmy, Heba Attia, Sadek Ahmed, Osama Saher
article en
3 citations

Abstract

<b>Introduction:</b> Vaginal candidiasis remains a recurrent fungal infection affecting millions of women worldwide, necessitating innovative local delivery systems to overcome poor drug solubility and mucosal barriers. This study introduces Dual-Functional Hybrid Cationic PEGylated Proniosomes (DHCPP) as a smart nano-platform designed to boost the vaginal delivery of Fenticonazole Nitrate (FTN). <b>Methods:</b> DHCPP systems were fabricated via the coacervation phase separation method and optimized using a full 2<sup>3</sup> factorial design, achieving a high desirability value of 0.931. The optimized DHCPP exhibited an encapsulation efficiency of 91.61%, particle size of 238.85 nm, and zeta potential of +58.85 mV, ensuring colloidal stability and efficient mucosal interaction. <b>Results:</b> <i>In-vitro</i> characterization using TEM and FTIR verified the formation of uniform spherical vesicles and successful FTN encapsulation without chemical incompatibility. Mucoadhesion testing revealed superior adhesive strength, indicating prolonged vaginal residence, while drug release followed a diffusion-controlled pattern. The optimized DHCPP was incorporated into a carbopol-based gel exhibiting pseudo-plastic rheology and pH compatibility with the vaginal environment. Multi-scale <i>ex vivo</i> and <i>in vivo</i> evaluations revealed a 2.36-fold permeation enhancement compared to FTN gel, consistent with deeper mucosal penetration observed via confocal microscopy. The microbiological assessment indicated a pronounced reduction in MIC and MFC values and a remarkable improvement in biofilm inhibitory effect, highlighting enhanced antifungal efficacy. Histopathological examination verified the mucosal safety of the optimized gel. <b>Conclusion:</b> The developed DHCPP represents an innovative, multifunctional, and biocompatible delivery system offering enhanced vaginal permeation, prolonged retention, and potent antifungal activity for the effective management of vaginal candidiasis.

Frontiers in PharmacologyVol. 16
Karolinska University Hospital (SE), University of Hertfordshire (GB), Cairo University (EG), Karolinska Institutet (SE)
No poverty
Openalex Percentile: Top 0%
Advanced Drug Delivery Systems
83.40
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.